Stratrix
Company data sheet · Baxter International

Baxter International: leaders came and went.

Industry
Surgical & Medical Instruments & Apparatus
Headquarters
United States
Ticker
BAX (NYSE)
Sources
SEC filings (1994–2026), Stratrix's verified Decision Cases, market data and official economic statistics for the United States
Data as of
November 2, 2026
  1. Leaders came and went. Baxter International filed 41 leadership changes since 2016, more than 93% of large manufacturers (the median is 20). The day after each, its shares moved a median 0.1 points against its sector. The news was rarely news.

Financial results

Fiscal yearRevenueNet income
2016$10.2 billion$5 billion
2017$10.6 billion$0.6 billion
2018$11.1 billion$1.5 billion
2019$11.4 billion$1 billion
2020$11.7 billion$1.1 billion
2021$12.1 billion$1.3 billion
2022$10.1 billion−$2.4 billion
2023$10.4 billion$2.7 billion
2024$10.6 billion−$0.6 billion
2025$11.2 billion−$1 billion

As reported in its annual filings. Losses in red.

Has Baxter International had layoffs?

Job cuts, severance and restructuring

None of Baxter International’s annual reports for 2023 to 2025 describes a layoff, workforce reduction or restructuring.

Reported in the company's financial data (XBRL), each linked to its filing
Fiscal year endedRestructuring charges
2016-12-31$285 million
2017-12-31$70 million
2018-12-31$117 million
2019-12-31$134 million
2020-12-31$111 million
2021-12-31$91 million
2022-12-31$144 million
2023-12-31$141 million
2024-12-31$146 million
2025-12-31$162 million

Baxter International has filed no restructuring notice (Form 8-K, Item 2.05) since 2016. Companies file one only for a cut they judge material, so many announced layoffs never appear as one. This page shows what the company reported to the SEC, not news reports or state layoff notices.

What has Baxter International acquired?

Deals its annual reports describe

BusinessDealWhenValue
Kidney Care business (Vantive Health LLC), sold to Carlyle
“On January 31, 2025, we completed the sale of our Kidney Care business to Carlyle for an aggregate purchase price of $3.80 billion in cash, subject to certain closing cash, working capital and debt adjustments.” 10-K for 2024
divestitureOn January 31, 2025, we completed the sale of our Kidney Care business to Carlyleaggregate purchase price of $3.80 billion in cash
BioPharma Solutions (BPS) business
“On September 29, 2023, we completed the sale of our BPS business and received cash proceeds of $3.96 billion from that transaction.” 10-K for 2024
divestitureOn September 29, 2023cash proceeds of $3.96 billion
Hillrom Holdings, Inc.
“We acquired Hillrom on December 13, 2021 and recognized $6.83 billion of goodwill and $6.03 billion of other intangible assets, including $1.91 billion of indefinite-lived intangible assets, in connection with that acquisition.” 10-K for 2024
acquisitionDecember 13, 2021—
Zosyn rights from a subsidiary of Pfizer Inc.
“Under the terms of the acquisition, we paid the acquisition price of $122 million and received specified intellectual property, including patent rights, in the first quarter of 2022 and received additional intellectual property, including the product rights to Zosyn, in the first quarter of 2023.” 10-K for 2024
acquisition—acquisition price of $122 million
Kidney Care business (now Vantive Health LLC)
“On January 31, 2025, we completed the sale of our Kidney Care business to Carlyle for an aggregate purchase price of $3.80 billion in cash, subject to certain closing cash, working capital and debt adjustments.” 10-K for 2025
divestitureJanuary 31, 2025$3.80 billion in cash
Hillrom
“In addition, we acquired Hillrom in 2021 and continue to work to fully integrate it into our business.” 10-K for 2025
acquisition2021—
Reported in the company's financial data (XBRL), each linked to its filing
Fiscal year endedCash paid for acquisitions (net of cash acquired)Goodwill from acquisitions
2016-12-31$48 million$3 million
2017-12-31$686 million$303 million
2018-12-31$268 million$32 million
2019-12-31$418 million$111 million
2020-12-31$494 million$34 million
2021-12-31$10.5 billion$6.79 billion
2022-12-31$258 million—
2023-12-31$4 million—
2024-12-31$14 million—
2025-12-31$9 million—

Deal filings since 2016

Who are Baxter International's competitors?

Who Baxter International names

Baxter International’s annual reports for 2023 to 2025 describe its competition by kind of business and do not name competing companies.

Who names Baxter International

Companies whose own annual reports name Baxter International as a competitor.

  1. Cantel Medical names it as “Baxter” · 2020

    “On a product basis, competitors include Evoqua, IsoPure, Baxter and Steris.” 10-K for 2020
  2. Cooper Companies · 2025

    “Larger companies such as Johnson & Johnson, Baxter International, Medtronic and Hologic have offerings that compete with our medical device products.” 10-K for 2025
  3. ICU Medical names it as “Baxter International ("Baxter")” · 2025

    “We compete with products and systems marketed by Becton Dickinson ("BD"), Baxter International ("Baxter"), B. Braun Medical, Inc.” 10-K for 2025
  4. Steris names it as “Baxter” · 2026

    “On a product basis, competitors include 3M, Baxter, Boston Scientific, Belimed, Ecolab, Fortive, Getinge, Karl Storz, Olympus, Ruhof, SteelCo, Stryker, Skytron and Wassenburg.” 10-K for 2026
  5. Stryker names it as “Baxter International Inc.” · 2025

    “We are one of five leading global competitors in Medical; the other four being Baxter International Inc., Zoll Medical Corporation, Medline Industries and Ferno-Washington, Inc.” 10-K for 2025

Layoffs, acquisitions, competitors and subsidiaries are read from Baxter International’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023), as of 2026-02-12.

The full data sheet · Data Plan

Everything behind these findings, ready for your board deck.

  • Market reaction to disclosed decisions: 72 decision filings since 2016, each linked to the SEC, with the share return against its sector and the US market the next day and the next year (47 with market data).
  • Economic context: 7 measures for the United States, every year since 2016, from the official sources.
  • Peer comparison: against 264 companies of its size in its sector.
  • Financial results: ten years of revenue, operating and net income, and every annual report, linked.
  • Methods and sources, so each number can be checked and cited.

The full data sheet downloads with the Data Plan. To see exactly what you get first, open the Boeing sample PDF or Excel.

More from Stratrix

The Business Model Wizard

Make the seven choices that define your model, test your numbers against real companies, and meet the rival AI would build against you.

Free · about twelve minutesBuild your Model Thesis →

Weekly email

Stratonomics, every Tuesday

One data story every Tuesday: what happened, what it means, and the figures you can quote. Free.

We'll email you a link to confirm. Unsubscribe anytime. Privacy policy.